Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06417775 · ClinicalTrials.gov registry record · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
A Phase 3 study of Migraine, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 496
- Enrollment target
- 20
- Study locations
NCT06417775 is a Phase 3 study of Migraine that is actively recruiting participants, run by AbbVie. The registered enrollment target is 496 participants, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (41% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT06417775, a Phase 3 study of Migraine, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 496 participants
- Enrollment target
- 20
- Study locations
Study Summary
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant is in treating menstrual migraine. Adverse Events and change in disease activity will be assessed. Ubrogepant is an investigational drug being developed for short-term prevention of menstrual migraine. Participants will be randomly assigned to one of the 2 groups to receive either ubrogepant or placebo. Around 496 adult female participants with menstrual migraine will be enrolled in approximately 100 sites in the United States and Puerto Rico. Participants will receive oral ubrogepant tablets once daily for 7 consecutive days starting 3 days prior to estimated onset of menses per cycle for 3 PMPs during double-blind period (16 weeks). Eligible participants may continue to receive oral ubrogepant tablets once daily for 7 consecutive days per cycle starting 3 days prior to estimated onset of menses during open-label extension period (52 weeks). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will collect data daily in electronic diaries and attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG Ubrogepant
- DRUG Placebo for Ubrogepant
Study Locations (20)
California
- Hope Clinical Research /ID# 257867 - Canoga Park
- Axiom Research /ID# 257833 - Colton
- Neuro Pain Medical Center /ID# 257155 - Fresno
- Axiom Research, LLC-Los Angeles /ID# 264085 - Glendale
- Sun Valley Research Center /ID# 257152 - Imperial
- Axiom Research - Irvine /ID# 264083 - Irvine
- Collaborative Neuroscience Research CNS /ID# 257828 - Los Alamitos
- Los Angeles Headache Center /ID# 257237 - Los Angeles
- Pharmacology Research Institute (PRI) - Newport Beach (Wake) /ID# 257158 - Newport Beach
- Artemis Institute for Clinical Research - San Diego /ID# 257134 - San Diego
- M3 Wake Research - Convoy /ID# 257897 - San Diego
- Optimus Medical /ID# 257856 - San Francisco
Arizona
- MD First Research - Chandler /ID# 262564 - Chandler
- Gilbert Neurology /ID# 260179 - Gilbert
- Foothills Research Center/CCT Research /ID# 260180 - Phoenix
- Trialmed-Synexus Clinical Research US, Inc. - Tucson /ID# 258309 - Tucson
Alabama
- Central Research Associates /ID# 260161 - Birmingham
- Rehabilitation & Neurological Services /ID# 275593 - Huntsville
Arkansas
- Preferred Research Partners /ID# 262786 - Little Rock
- Preferred Research Partners /ID# 273128 - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 2024-09-10 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06417775
The ClinicalTrials.gov registry entry for NCT06417775 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 496 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (41% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Ubrogepant is the first listed.
NCT06417775 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06417775 about?
NCT06417775 is a clinical study titled "Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine". A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perim...
What is the current status of trial NCT06417775?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 496 participants. The study started on 2024-09-10. Estimated completion is 2027-09.
What conditions does trial NCT06417775 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06417775?
The interventions under investigation include: Ubrogepant (DRUG), Placebo for Ubrogepant (DRUG).
Who is sponsoring clinical trial NCT06417775?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06417775 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
-
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.